Mar 3, 2025 · Trastuzumab deruxtecan is FDA-approved for the treatment of HER2-positive metastatic breast cancers that have progressed on at least one past HER2-targeted therapy …

Trastuzumab (brand name: Herceptin) is a targeted therapy known as a monoclonal antibody, a modified version of an immune system protein, that can attach to proteins on HER2-positive …

Learn about Herceptin® (trastuzumab), a targeted therapy approved for HER2+ metastatic breast cancer treatment. See full safety & Boxed Warnings for more information.

Apr 17, 2025 · Learn how targeted therapies, including monoclonal antibodies (such as Herceptin or Trastuzumab), can be used to treat breast cancer.

Trastuzumab (Herceptin) is a targeted therapy for treating breast cancer. Find out when it's used, how it works and possible side effects.

Aug 10, 2021 · Targeted therapy for HER2-positive breast cancer In about 15% to 20% of breast cancers, the cancer cells make too much of a growth-promoting protein known as HER2. …

Dec 23, 2025 · Herceptin (chemical name: trastuzumab) is a HER2 inhibitor targeted therapy. Herceptin works against HER2-positive breast cancers by blocking the ability of the cancer …

Jun 17, 2025 · The current treatment landscape for HER2-positive metastatic breast cancer has evolved significantly, with recent updates further refining patient care strategies. Historically, …

Sep 29, 2025 · Hormone therapy, chemotherapy, targeted therapy, and immunotherapy are the most effective treatments for metastatic (stage 4) breast cancer. These therapies use drugs to …

Apr 14, 2024 · Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and …